Company: BWAY
Filing Date: 2025-09-30
Form Type: 6-K
Source: 0001171843-25-006185
Chunk: 13

Company: Brainsway Ltd.
Filing Date: 2025-09-30
Form: 6-K
Chunk 13
---
----|----------------:|:----|:--|-----------------------:|
| For the computation of basic earnings per share   |     |                37,705,678 |     | $ |                  3,134 |   |     |      33,282,725 |     | $ |                    711 |
| Effect of potential dilutive ordinary shares      |     |                 1,356,991 |     |   |                   (303 | ) |     |         709,933 |     |   |                      — |
| For the computation of diluted earnings per share |     |                39,062,669 |     | $ |                  2,831 |   |     |      33,992,658 |     | $ |                    711 |

| 9 |

BRAINSWAY LTD. AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED UNAUDITED INTERIM FINANCIAL STATEMENTS

U.S. dollars in thousands (except share and per share data)

NOTE 10: BALANCES AND TRANSACTIONS WITH RELATED PARTIES

For transactions including change in warrant terms issued to related parties, see Note 4c.

NOTE 11: SUBSEQUENT EVENTS

| 1. | On August 18, 2025, the Company completed an initial strategic investment by means of a $5,000 convertible                                 
 loan to, along with an option to acquire, Neurolief Ltd. (“Neurolief”), developer of a non-invasive, multi-channel brain neuromodulation   
 platform that is designed for use at home. The agreement provides for potential additional milestone-based funding to Neurolief, including 
 a second tranche of up to a $6,000 convertible loan upon FDA approval of Neurolief’s Proliv Rx system for MDD treatment, and a third       
 tranche consisting of up to a $5,000 equity investment upon Neurolief achieving an agreed-upon revenue milestone. BrainsWay has also been  
 granted a “call option” to acquire all outstanding equity interests in Neurolief during clearly defined exercise windows,                  
 at a price based on the greater of a specified enterprise value or a revenue multiple, with the values varying depending on timing of      
 exercise.                                                                                                                                  |

| 2. | On August 19, 2025, the Company entered into a strategic equity financing agreement with Axis Management Company,                                                                                                                               
 Inc. (“Axis Integrated Mental Health”), a management